Shots:
- IDEAYAhas entered into an additional clinical study collaboration and supply agreement with Gilead Sciences to evaluate the efficacy and safety of IDE397 + Trodelvy in MTAP-Deletion NSCLC
- IDEAYA is currently enrolling patients in a monotx. expansion study for IDE397 in MTAP-deletion NSCLC and urothelial cancer, alongside the P-I/II study evaluating IDE397 with Trodelvy in UC and NSCLC. The company also expects to launch a wholly-owned clinical combination study of IDE397 and IDE892, in the 2H’25
- IDE397 is a selective methionine adenosyl transferase 2a (MAT2A) inhibitor for patients with solid tumours with MTAP deletion
Ref: Prnewswire | Image: IDEAYA & Gilead Sciences
Related News:- IDEAYA Biosciences Partners with Hengrui Pharma to Develop SHR-4849 for Treating SCLC and NET Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
